Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: a bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey.
Fiche publication
Date publication
mars 2021
Journal
Clinics and research in hepatology and gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LEPAGE Côme
Tous les auteurs :
Basile D, Gallois C, Puglisi F, Cohen R, Goere D, Aprile G, Lepage C, Laurent-Puig P, Maio MD, Lecomte T, Pernot S, Zaanan A, Taieb J
Lien Pubmed
Résumé
Increasing evidence shows that circulating tumor DNA (ctDNA) is a valuable tool in providing molecular, prognostic, predictive and dynamic information in colorectal cancer (CRC) patients. This study aimed to make a picture of knowledge, practice, attitudes and expectations about ctDNA in CRC patients.
Mots clés
circulating tumor DNA, colorectal cancer, ctDNA, liquid biopsy
Référence
Clin Res Hepatol Gastroenterol. 2021 Mar 27;:101681